Chimeric Antigen Receptor T-Cell Therapy in Aggressive B-Cell Lymphoma

Mark P Hamilton; David B Miklos

doi:10.1016/j.hoc.2023.05.007

Chimeric Antigen Receptor T-Cell Therapy in Aggressive B-Cell Lymphoma

Hematol Oncol Clin North Am. 2023 Dec;37(6):1053-1075. doi: 10.1016/j.hoc.2023.05.007. Epub 2023 Jun 20.

Authors

Mark P Hamilton¹, David B Miklos²

Affiliations

¹ Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address: mphamilt@stanford.edu.
² Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.

PMID: 37349153
DOI: 10.1016/j.hoc.2023.05.007

Abstract

Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary therapy increasingly used in the treatment of non-Hodgkin B-cell lymphoma. This review focuses on the use of CAR T-cell therapy in aggressive B-cell lymphoma including clinical indications, known short- and long-term toxicity, mechanisms of CAR T-cell efficacy and tumor resistance, and future directions in the treatment of aggressive lymphoma with CAR T-cell therapy.

Keywords: Aggressive lymphoma; CAR T-cell; CAR T-cell resistance; CAR T-cell toxicity; CD19; Large B-cell lymphoma; Review.

Publication types

Review